We are excited to share the latest update on Mile High Labs Novel Foods Application RP349: Over 1,300 Stock Keeping Units (SKUs) have moved to the “validated” status on the UK Novel Foods Public List as of 31 May 2023 1 . This milestone further demonstrates Mile High Labs’ commitment to adhering to the highest standards of quality and safety in the production of CBD products.
“I am delighted that we have reached this crucial milestone of validation in the Novel Foods process. Our team has worked tirelessly to ensure that all our standards have remained our priority and we continue to pride ourselves in producing one of the highest CBD ingredient quality levels in the industry for our customers.”
John Wallace, Managing Director, International Operations, Mile High Labs.
Validation: A Crucial Step in Novel Foods Application
Validation is a critical phase in the Novel Foods application process. It is an acknowledgement by the Food Standards Agency (FSA) that a comprehensive dossier has been compiled for a product, containing all the necessary data to proceed to the next stage. This includes detailed information about the product’s ingredients, production processes and safety assessments. This validation of our ingredients and over 1300 SKUs demonstrates that we have provided all required detailed information for our range of products, and we are ready to move towards final authorisation.
Partnerships in Progress: Collaboration with Renowned Suppliers
Mile High Labs has been working in close collaboration with partners to successfully pass through the validation stage. The list of validated SKUs includes a diverse range of CBD finished goods 1. This collective achievement highlights the strength of our partnerships and our shared dedication to bringing high-quality and safe CBD products to the market.
What’s Next: Risk Assessment and Authorisation
As we celebrate this significant step forward, we are also gearing up for the next stages of the process. Following validation, the next step is risk assessment. In this phase, the FSA will examine the safety of CBD derived products in detail, looking at aspects such as toxicity and allergenicity, among others.
Once our application passes the risk assessment phase, we will be granted authorisation. Mile High Labs is looking forward to navigating the next stages with the same commitment to quality and safety that we have demonstrated throughout this process.
Conclusion
Our key focus remains on ensuring the safety, quality, and efficacy of our products. We are grateful for our partners who have joined us on this journey and who are equally committed to maintaining these values. We look forward to keeping you updated on our continued progress!
Want to stay ahead of the latest cannabinoid industry trends? Subscribe to our newsletter and never miss a post!
